Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development

Author

M. Voss

h-index 10 View on Semantic Scholar

We have 4 of 58 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.

BACKGROUND Pembrolizumab plus lenvatinib is a first-line standard of care for advanced clear-cell renal-cell carcinoma (ccRCC). The phase 3 LITESPARK-012 study (NCT04736706) evaluated efficacy and safety of adding belzutifan (HIF-2α inhibitor) or quavonlimab (anti-CTLA-4) to this regimen. PARTICIPANTS AND METHODS Adu...

B. Rini, T. Choueiri, M. Voss et al. · 0 citations
Open access Sep 2026

24 A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)

Abstract Background There is a need for novel systemic therapies in patients with metastatic renal cell carcinoma (RCC) who progress on standard agents. A hallmark of clear cell RCC (ccRCC) is von Hippel Lindau (VHL) inactivation which affects downstream targets including vascular endothelial growth factor (VEGF). It a...

Sahil D. Doshi, Y. Ged, Andrea Knezevic et al. · 0 citations
Review Open access Sep 2026

85 Phase 3 LITESPARK-033 (NCT07227402) Study of Belzutifan Plus Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell Renal Cell Carcinoma During or After Adjuvant Anti–PD-(L)1 Therapy

A randomized, multicenter, open-label phase 3 LITESPARK-033 study is designed to evaluate the efficacy and safety of belzutifan plus zanzalintinib versus cabozantinib in participants with advanced clear cell RCC who experienced recurrence during or after anti–PD-(L)1 adjuvant therapy.

T. Choueiri, T. Powles, M. Voss et al. · 0 citations
Open access Aug 2026

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Using large, unselected pan-cancer cohorts and integrated tumor and genomic analysis can help refine the phenotype of rare cancer predisposition syndromes and suggest novel cancer associations, including BAP1 PVs in hepatobiliary cancers and FLCN in colorectal cancer.

M. Carlo, Andrew Schroeder, Jie Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.